Compounded GLP-1 medications: risks, regulations, and what to ask

Compounded GLP-1 medications have become one of the most contentious topics in weight-management care. For patients, the appeal is straightforward — compounded semaglutide and tirzepatide are often significantly cheaper than the branded versions, and during drug shortages they were sometimes the only available option. For regulators, the concern is equally straightforward — these products lack the manufacturing controls, clinical testing, and ongoing surveillance that FDA approval requires. This article explains both sides with specific data so you can make an informed decision.

What compounding actually means

Compounding is the practice of creating a medication tailored to an individual patient's needs, typically when a commercially available product is not suitable. It has legitimate uses — for example, creating a liquid formulation for a patient who cannot swallow pills, or removing an allergen from a drug's inactive ingredients. Compounding pharmacies operate under different regulatory frameworks than the manufacturers of FDA-approved drugs.

There are two legal categories of compounding pharmacies, and the distinction matters significantly for patient safety:

• 503A pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act. They prepare medications based on individual patient prescriptions. They are primarily regulated by state boards of pharmacy, not the FDA. Products are made in smaller batches and are not subject to FDA current Good Manufacturing Practice (cGMP) requirements.

• 503B outsourcing facilities operate under Section 503B. They can produce larger batches without patient-specific prescriptions and are registered with and inspected by the FDA. They must comply with cGMP requirements, report adverse events to the FDA, and submit to regular inspections. This is a higher regulatory standard than 503A, though still significantly lower than the approval pathway for branded drugs.

The practical difference: a 503B facility undergoes FDA inspections and must follow manufacturing standards, while a 503A pharmacy is primarily overseen by state regulators whose inspection frequency and rigor vary widely. Both can legally compound GLP-1 medications under specific circumstances, but the safety profiles are not equivalent.

The regulatory timeline: how we got here

The legal basis for compounding GLP-1 medications has shifted rapidly. Understanding this timeline is essential for evaluating whether a compounded product is being offered legally:

• Drug shortage era (2022-2024): Both semaglutide and tirzepatide were placed on the FDA drug shortage list due to extraordinary demand. Under federal law, drugs on the shortage list can be compounded by both 503A and 503B pharmacies without the usual restrictions that apply to copies of commercially available products.

• Semaglutide removed from shortage list (February 2025): The FDA determined that the semaglutide shortage had resolved and removed it from the shortage list. This triggered a legal change — compounding pharmacies could no longer compound semaglutide simply because it was in shortage. An enforcement discretion period followed.

• Enforcement discretion ends (April-May 2025): The FDA's enforcement discretion period for compounded semaglutide ended, meaning pharmacies that continued compounding without a valid legal basis (such as a documented patient-specific medical need) were in violation of federal law.

• Tirzepatide follows a similar path: Tirzepatide's shortage status has also been under review, with the regulatory trajectory following the same pattern as semaglutide.

FDA adverse event data: the numbers

The FDA has published adverse event data that provides a concrete picture of reported safety problems with compounded GLP-1 products. As of July 2025:

• 605 adverse event reports have been associated with compounded semaglutide products.

• 545 adverse event reports have been associated with compounded tirzepatide products.

These numbers should be interpreted carefully. Adverse event reports are not proof of causation — they indicate that someone experienced a health problem while using the product and that the event was reported to the FDA. The actual number of adverse events is likely higher than reported, as the FDA's voluntary reporting system captures only a fraction of real-world events. However, the volume of reports is sufficient for the FDA to have issued multiple safety communications about compounded GLP-1 products.

Specific safety problems identified

Beyond the aggregate numbers, the FDA and published reports have identified several categories of specific safety problems with compounded GLP-1 products:

Dosing errors

One of the most dangerous reported problems involves patients accidentally administering 5 to 20 times the intended dose. This typically happens because compounded products use multi-dose vials with syringes that patients must measure themselves, unlike the pre-filled autoinjector pens used for branded Wegovy and Zepbound. Syringe confusion — misreading unit markings, using the wrong syringe type, or confusing milligrams with units — has led to severe overdoses requiring emergency medical attention. Symptoms of GLP-1 overdose include intractable nausea and vomiting, severe hypoglycemia, pancreatitis, and dehydration.

Sterility failures

Injectable medications must be sterile. FDA inspections of compounding pharmacies have found sterility failures including inadequate cleanroom conditions, insufficient testing of finished products, and contaminated compounding environments. Injecting a non-sterile product can cause local injection site infections, abscesses, or systemic infections including sepsis.

Ingredient quality concerns

The FDA has flagged the use of food-grade or research-grade ingredients in injectable compounded products rather than pharmaceutical-grade ingredients. Empower Pharmacy, one of the largest 503B compounding facilities for GLP-1 products, received its fourth FDA warning letter in April 2025 citing manufacturing and quality concerns. The use of inappropriate ingredient grades in an injectable product introduces unknown impurities and degradation products that could cause allergic reactions, injection site reactions, or systemic toxicity.

Salt form differences

Some compounding pharmacies have produced semaglutide sodium rather than semaglutide base (the active ingredient in FDA-approved products). Semaglutide sodium is a different chemical entity with different molecular weight and potentially different pharmacokinetic properties. The FDA has stated that semaglutide sodium is not the same as the semaglutide in Wegovy or Ozempic, and products containing semaglutide sodium cannot be considered copies of the approved drug.

What is still legally permitted

Compounding of GLP-1 medications is not entirely prohibited. Under federal law, compounding may still be legally permissible in specific circumstances:

• Documented allergy to an inactive ingredient: If a patient has a documented allergy to a specific inactive ingredient (excipient) in the commercially available product that cannot be addressed by switching to a different FDA-approved product, a compounding pharmacy may prepare a version without that ingredient.

• Medically necessary dose not commercially available: If a prescriber documents that the patient requires a specific dose that is not available as a commercial product and cannot be achieved by combining available doses, compounding may be justified.

• Patient-by-patient basis: The legal basis requires individual clinical justification. Blanket prescribing of compounded GLP-1 medications to all patients — as some telehealth platforms have done — does not meet the legal standard.

The key distinction is between compounding driven by a documented individual medical need versus compounding driven by cost savings or convenience. Only the former has a clear legal basis after the shortage period ended.

Red flags when evaluating a compounded GLP-1 provider

If you are considering a provider that offers compounded GLP-1 medications, the following signs should raise concerns:

• The provider only offers compounded products and does not prescribe or discuss branded alternatives.

• There is no discussion of your specific medical need for a compounded product — the compounded version is simply presented as the standard option.

• The provider cannot tell you which pharmacy compounds the medication, or whether it is a 503A or 503B facility.

• The product arrives without clear labeling showing the exact concentration, lot number, expiration date, and pharmacy name.

• The product requires you to measure doses with a syringe rather than using a pre-filled autoinjector pen.

• The price is significantly lower than brand-name products without explanation of the regulatory basis for compounding.

• The provider makes claims that the compounded product is "the same as" or "equivalent to" branded Wegovy or Zepbound.

• The provider started or continued offering compounded semaglutide after May 2025 without documenting individual patient-specific need.

Questions to ask your provider about compounded GLP-1 products

If compounding is being recommended for a documented medical reason, these are the questions to ask to evaluate the safety and legitimacy of the product:

• Is the compounding pharmacy registered as a 503A or 503B facility? 503B is preferred for safety oversight.

• Does the pharmacy submit to regular FDA inspections, and when was the last inspection?

• Does the product undergo third-party potency and sterility testing? Can the pharmacy provide certificates of analysis?

• Which salt form of semaglutide does the pharmacy use — semaglutide base (matching the FDA-approved product) or semaglutide sodium?

• What are the storage requirements? Injectable GLP-1 products typically require refrigeration. Products that claim room-temperature stability may not have adequate stability data.

• What is the beyond-use date (expiration) of the compounded product? Compounded products typically have shorter expiration dates than commercially manufactured drugs.

• What is the specific medical justification for prescribing a compounded product rather than a branded one?